Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial

The doxorubicin-docetaxel combination is active in breast cancer; the aim of the present study was to evaluate the complete response rate and safety profile of the doxorubicin and docetaxel regimen as first-line chemotherapy in metastatic breast cancer patients. Forty-three patients entered the stud...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2004-09, Vol.24 (5B), p.3257-3261
Hauptverfasser:	MATTIOLI, R, LIPPE, P, LAICI, G, BALLETTA, A, SILVA, R. R, MASSACESI, C, CAPPELLETTI, C, NACCIARRITI, D, BISONNI, R, GRAZIANO, F, MENICHETTI, E. T, IMPERATORI, L, TESTA, E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Disease-Free Survival Doxorubicin - administration & dosage Doxorubicin - adverse effects Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Neoplasm Metastasis Survival Rate Taxoids - administration & dosage Taxoids - adverse effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!